Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Register with your email to read the full article.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
More in BRIEFING
BRIEFING
First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production
Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.
BRIEFING
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...
BRIEFING
AstraZeneca Spinout Viela Bio Fetches $250 M, Pushes Pipeline Autoimmune Drugs in Clinical Study
AstraZeneca subsidiary, MedImmune has spun out a new inflammation- and autoimmunity-focused biotech, Viela Bio with six molecules from MedImmune. The ...
BRIEFING
FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone
US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. ...
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply